Skip to main
University-wide Navigation

New UK Research May Offer Hope for Alzheimer’s Patients

UK Neuroscience Professor Greg Gerhardt's new research program will provide answers to questions about the role of neurotransmitters in the progression of Alzheimer’s disease.

Research Establishes a New Method to Predict Individual Risk of Cognitive Decline

Their work shows that direct measures of brain signatures during mental activity are more sensitive and accurate predictors of memory decline than current standard behavioral testing.

UK Researcher Finds Alzheimer’s Patients ‘Get Hooked on a Feeling’ With Music

Newly published research has found familiar music can elicit an extended emotional response in patients with Alzheimer’s-type dementia. The findings from this potential new approach were featured in the Journal of Alzheimer’s Disease.

UK Study Potentially Links Low Blood Amylin Level to Reduced Progression of Alzheimer’s Disease

Florin Despa says that a major scientific goal is to understand whether the same factors that are involved in age-related metabolic disorders such as type-2 diabetes may also play a role in the development and progression of cognitive decline and dementia.

'Behind the Blue': Dr. Peter Nelson Discusses UK’s Leading Efforts on Alzheimer’s and Dementia Research

Dr. Peter Nelson, of the University of Kentucky’s Sanders-Brown Center on Aging, has spent the last 15 years in the Commonwealth helping to lead the fight against Alzheimer’s and dementia inducing brain disease.

10th Annual Sanders-Brown Markesbery Symposium on Aging and Dementia Taking Place Virtually

In the sessions for both the scientific and community audience, attendees will have the opportunity to hear clinicians and researchers from UK and other institutions share current findings, trends, and latest updates on dementia and aging disorders.

Butterfield Recognized as a Leading Alzheimer’s Expert

Butterfield is among the top 0.007% of scholars worldwide based on authorship of Alzheimer’s-related publications indexed in the PubMed database for the past 10 years. He ranks tenth out of nearly 150,000 scholars worldwide and sixth in the U.S.

Sanders-Brown Research Discovers New Pathway in TDP-43 Related Dementias

Selenica says their study is the first to provide a novel pathway and identify potential therapeutic targets for TDP-43 proteinopathies – especially in Alzheimer’s disease and the newly characterized form of dementia known as LATE.

Sanders-Brown Study Leads to Potential New Treatment Approach for Alzheimer’s Disease

Through the group's work, they found that the therapeutic targeting of TREM2 using a TREM2-activating antibody leads to the activation of microglia, recruitment of microglia to amyloid plaques, reduced amyloid deposition, and ultimately improved cognition.

UK’s Sanders-Brown, Penn Researchers Provide Insights into Newly Characterized Form of Dementia

“We used to think that aging-related memory and thinking decline meant one thing: a disease called Alzheimer’s disease. Now we know that the disease we were calling Alzheimer’s disease is actually many different conditions, often in combination."

Filter News